

Supplemental Table 1: Bacterial strains used in this study

V583	Parental strain	Clinical isolate (1)
IH06	V583 Δ ef0114	(2)
AH03	V583 Δ ef0362-61	(2)
AH01	V583 Δ ef2863	(2)
AH09	V583 Δ ef0114 Δ ef0362-61 Δ ef2863 (Δ TM)	(2)
EK49	V583 Δ ef0114::ef0114	This study
EK50	V583 Δ ef0114 Δ ef0362-61 Δ ef2863::ef0114	This study
AH03R	V583 Ω ef0362-61	(2)
EH01	V583 Δ ccpA	(3)
VI70	V583 Δ ccpA Δ ef0114	(2)
AH05	V583 Δ ccpA Δ ef0362-61	(2)
AH10	V583 Δ ccpA Δ ef2863	(2)
IH09	V583 Δ ccpA Δ ef0114 Δ ef0362-61	(2)
IH12	V583 Δ ccpA Δ ef0362-61 Δ ef2863	(2)
IH08	V583 Δ ccpA Δ ef0114 Δ ef2863	(2)
IH13	V583 Δ ccpA Δ ef0114 Δ ef0362-61 Δ ef2863	(2)
EK40	V583 Δ ccpA Δ ef0114::ef0114	This study
IH10	V583 Δ mptBACD	(3)
EK02	V583 Δ ef1516	(3)
IH10R	V583 Ω mptBACD	(3)
EK48	V583 Δ mptBACD Δ ef1516	This study
EK54	V583 Δ mptBACD Δ ef1516::mptBACD	This study
EK55	V583 Δ mptBACD Δ ef1516::ef1516	This study

SP27	V583 Δ <i>efl317</i>	This study
EK47	V583 Δ <i>efl317::efl317</i>	This study
ZA05	V583 Δ <i>efl0466</i>	This study
EK46	V583 Δ <i>efl0466::efl0466</i>	This study

Supplementary References

1. Sahm DF, Kissinger J, Gilmore MS, Murray PR, Mulder R, Solliday J, Clarke B. 1989. In vitro susceptibility studies of vancomycin-resistant *Enterococcus faecalis*. *Antimicrob Agents Chemother* 33:1588-91.
2. Keffeler EC, Iyer VS, Henderson AJ, Huck IL, Schwarting N, Cortez A, Hancock LE. 2021. Activity of CcpA-regulated GH18 family glycosyl hydrolases that contribute to nutrient acquisition and fitness in *Enterococcus faecalis* Infection and Immunity (*in press*).
3. Keffeler EC, Iyer VS, Parthasarathy S, Ramsey MM, Gorman MJ, Barke TL, Varahan S, Olson S, Gilmore MS, Abdullahi ZH, Hancock EN, Hancock LE. 2021. Influence of the Alternative Sigma Factor RpoN on Global Gene Expression and Carbon Catabolism in *Enterococcus faecalis* V583. *mBio* 12.

Supplemental Table 2: Oligonucleotides used in this study

Primer	Sequence (5'-3')
EF0114P1	GAGAG <u>AATTCCGT</u> GAAGTTACACTGAACAAG
EF0114P4	GAGACT <u>GCAGCTTGATTGACAGCTTCCAGC</u>
EF0114Up	GATGGGAAGCCAGTAATAAGAG
EF0114Down	CGTGCTGGCATATAATTGACC
MptBACDP1	GAGAG <u>AATTCCGAAGACTATGAAATTATTGCG</u>
MptBACDP4	GAGACT <u>GCAGCAGTCATTCCATGATGTTGT</u>
MptBACDUp	TAGACTGGCATTAGAAGTGA
MptBACDDown	GCAATTCTTCATACGATTACG
EF1516P1	GAGAG <u>AATTCCAATGTGGTGTACAATGGTTAC</u>
EF1516P4	CTCT <u>GCATGCATCAGTTACATCCCTCTAGT</u>
EF1516Up	CGAGCACATATAAGTATGCCT
EF1516Down	GAAGGCCTAACTCTTCTGCTT
EF1317P1	GAGAG <u>AATTCTTCACCTATAAGCCGATAAG</u>
EF1317P2	TCT <u>CGGATCCATG TTTCATCTTCATCCTCTTTC</u>
EF1317P3	GAGAG <u>GGATCCGCATAAGACACACAAGAAAAAGCTT</u>
EF1317P4	TCT <u>CCTGCAGCATCTTAGAAGCCAAAGCCTT</u>
EF1317Up	AGATACGGACTGGAAAAATAT
EF1317Down	CTGTCAACACTCCTTATATGACG
EF0466P1	GAGAG <u>AATTCCGTTGGAAATGACACACACAAGAC</u>
EF0466P2	GAGACT <u>GCAGTGCATTGCTACACGGATAATTG</u>
EF0466P3	GAGACT <u>GCAGAACCATCAAGATGTTGTTGTA</u>
EF0466P4	GAG <u>AGCATGCCTTACTTATCACCTTCTTCTAAC</u>

EF0466Up AGGTCGAACAGAACAAAGGTC

EF0466Down GTGACCATTCTGCTTCGACTT

Underlined sequences depict restriction sites used for cloning purposes

Supplemental Table 3: Plasmids used in this study

Plasmid	Description	Reference
pLT06	Markerless exchange vector; chloramphenicol resistance	(1)
pEK09	pLT06 + engineered <i>ef0114</i> complement	This study
pEK04	pLT06 + engineered <i>ef1516</i> deletion	(2)
pEK68	pLT06 + engineered <i>mptBACD</i> complement	This study
pEK61	pLT06 + engineered <i>ef1516</i> complement	This study
pSP20	pLT06 + engineered <i>ef1317</i> deletion	This study
pEK60	pLT06 + engineered <i>ef1317</i> complement	This study
pZA12	pLT06 + engineered <i>ef0466</i> deletion	This study
pEK62	pLT06 + engineered <i>ef0466</i> complement	This study
pEK33	pET21b + EF0114 (full length) + His6 overexpression	(3)
pEK34	pET21b + EF0114 (α) + His6 overexpression	(3)
pEK36	pET21b + EF0114 (γ) + His6 overexpression	(3)
pEK37	pET21b + EF0114 ($\alpha+\beta$) + His6 overexpression	(3)
pEK38	pET21b + EF0114 ($\beta+\gamma$) + His6 overexpression	(3)
pEK47	pET21b + EF0114 E186Q + His6 overexpression	(3)
pEK48	pET21b + EF0114 E662Q + His6 overexpression	(3)

Supplementary References

1. Thurlow LR, Thomas VC, Fleming SD, Hancock LE. 2009. *Enterococcus faecalis* capsular polysaccharide serotypes C and D and their contributions to host innate immune evasion. *Infection and Immunity* 77.
2. Keffeler EC, Iyer VS, Parthasarathy S, Ramsey MM, Gorman MJ, Barke TL, Varahan S, Olson S, Gilmore MS, Abdulla ZH, Hancock EN, Hancock LE. 2021. Influence of the Alternative Sigma Factor RpoN on Global Gene Expression and Carbon Catabolism in *Enterococcus faecalis* V583. *mBio* 12.

3. Keffeler EC, Iyer VS, Henderson AJ, Huck IL, Schwarting N, Cortez A, Hancock LE. 2021. Activity of CcpA-regulated GH18 family glycosyl hydrolases that contribute to nutrient acquisition and fitness in *Enterococcus faecalis* Infection and Immunity (*in press*).